NASDAQ: GILD

Explore the latest insights on NASDAQ: GILD and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NASDAQ: GILD’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

China's Ministry of Commerce (MOFCOM) and the Ministry of Science and Technology (MOST) jointly launched a public consultation on proposed revisions to the Catalogue of Technologies Prohibited or Restricted from…

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility

CompanyDeals

Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m

Show More